Tharimmune, Inc.
Tharimmune, Inc. (THAR) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · THAR · as of Jun 9, 2026
Key Statistics
Explore Tharimmune, Inc. Data
thar stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 1 · Buy rate: 0.0%
Competitors & Peers
thar competitorsTHAR
ADAP
ADTX
AIMD
ANL
APLMStock Performance
Full HistoryAbout Tharimmune, Inc.
Tharimmune, Inc. is a biotechnology firm operating in the clinical stage, focused on creating therapeutic solutions for rare, inflammatory, and oncological conditions. Its preclinical immuno-oncology …
what is tharimmune, inc. · thar stock overview · tharimmune, inc. company profile · who is tharimmune, inc. ceo · thar NASDAQ · tharimmune, inc. headquarters · tharimmune, inc. business segments
About Stock Overview & Key Data
Tharimmune, Inc. (THAR) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jan 12, 2022. As of the latest trading session, THAR stock price is $3.54, with a market capitalization of $139.9M. The stock has returned +158.39% over the past 12 months and +16.83% year-to-date.
According to 1 Wall Street analysts, the consensus rating for Tharimmune, Inc. stock is Hold, with an average 12-month price target of $—. In fiscal year 2025, Tharimmune, Inc. reported revenue of — and net income of -$35.9M. For detailed data — including Tharimmune, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Tharimmune, Inc. (THAR) stock price is $3.54. The stock is traded on NASDAQ under the ticker symbol THAR. The 52-week range is $0.95 – $9.08.